New Treatment Breakthrough: Amivantamab Plus Lazertinib for Advanced Lung Cancer – Timothy A. McCarthy, MD

A groundbreaking study published in June 2024 in The New England Journal of Medicine has introduced a promising new treatment for a specific type of advanced lung cancer. The research, co-authored by Alex Spira, MD, PhD, FACP, FACSO, Medical Oncologist and Co-Director of The Virginia Cancer Specialists Research Institute, highlights the combination of two drugs, […]

Enhancing Lung Cancer Treatment: The Promise of Perioperative Immunotherapy – Samantha DiBenedetto, MD

Introduction: Lung cancer remains one of the most challenging and life-threatening diseases; however, several exciting treatment advances show promising benefits. A recent study in which Virginia Cancer Specialists participated under the research leadership of Dr. Alex Spira, the AEGEAN trial, was published in the New England Journal of Medicine (NEJM) earlier this month and has shed light […]

November is Lung Cancer Awareness Month – Advancements in Lung Cancer Treatment

November is Lung Cancer Awareness Month. In recent years, lung cancer treatment has taken incredible steps forward, thanks to breakthrough research and early detection. Here are some of the latest advancements in treating lung cancer. Your browser does not support the video tag.

Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP 

Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP  Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib  – See the […]